Garth Lees-Rolfe
Independent DirectorMr. Garth Lees-Rolfe, CPA is Chief Financial Officer, Treasurer and Secretary of ABLi Therapeutics, Inc. He serves as Independent Director of Ludwig Enterprises, Inc. since June 23, 2025. He served as Chief Financial Officer at Inhibikase Therapeutics, Inc. since April 1, 2024 until April 2025. Mr. Lees-Rolfe served as Vice President of Finance at Inhibikase Therapeutics, Inc. from November 2022 until his appointment as Chief Financial Officer. Mr. Lees-Rolfe previously served as the Vice-President, Finance for F-Star, Inc., a publicly traded global clinical-stage biotech company from December 2021 to November 2022. Prior to that, Mr. Lees-Rolfe worked for 16 years in public practice, most of which was with Ernst & Young, most recently as Senior Manager from 2016 to 2021. Mr. Lees-Rolfe earned a Bachelor of Business from the Queensland University of Technology and a Graduate Certificate in Applied Finance from Kaplan Professional. He is a licensed Certified Public Accountant in the state of Massachusetts and a licensed Chartered Accountant of Australia and New Zealand.
Positions
- Company NameLudwig Enterprises, Inc.Stock CodeLUDGPositionIndependent Director
